US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.36

+1.022.41%

Post-market: 43.360.00000.00%16:10 EDT

Volume:513

Turnover:22.27K

Market Cap:32.52M

PE:- -

High:43.40

Open:43.40

Low:43.28

Close:42.34

52wk High:43.40

52wk Low:29.50

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.75

T/O Rate:0.07%

Dividend:0.14

Dividend Rate:0.33%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Metabolic disorder biotech Vogenx targets $75 million IPO at $11-$13 per share

Natera CFO Michael Burkes Brophy Disposes of USD 1.29 Million in Common Shares

Adaptive Biotechnologies Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Adaptive Biotechnologies Q2 Net Loss Widens to $39.9 Million; Revenue Rises 22% to $71.6 Million

Adaptive Biotechnologies Shares Drop 6.9% in Extended Trading After Posting Quarterly Results

THOMSON REUTERS

Guardant Health to Present at Canaccord Genuity Growth Conference Fireside Chat

Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate

Benzinga Earnings

Adaptive Biotechnologies Q2 EPS USD -0.25

Adaptive Biotechnologies Expects Fy2026 Mrd Revenue $268 Mln-$278 Mln

THOMSON REUTERS

Adaptive Biotechnologies Q2 Adjusted Ebitda USD -700 Thousand

THOMSON REUTERS

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

THOMSON REUTERS

ABL Diagnostics Reports Share Block Sale by Main Shareholder and Reaffirms Market Visibility Push

Natera’s New ctDNA-Guided Immunotherapy Trial Could Redefine Cancer Treatment Cycles

Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million

Krystal Biotech Updates Financial Calendar with Quarterly Results Release, Conference Call

Natera (NTRA) Gets a Buy from BTIG

J.P. Morgan Remains a Buy on Natera (NTRA)

Natera reports results from multicenter study in MCC

Natera Notifies Availability of Press Release on Signatera Merkel Cell Carcinoma Study in JAMA Dermatology

Is Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HELX/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.3608,"timestamp":1787688000000,"preClose":42.3399,"halted":0,"volume":513,"hourTrading":{"tag":"盘后","latestPrice":43.3608,"preClose":43.3608,"latestTime":"16:10 EDT","volume":6,"amount":260.1648,"timestamp":1787688604286,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02411200782240859,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":1.0209,"latestTime":"08-25 19:03:45 EDT","open":43.4001,"high":43.4001,"low":43.275,"amount":22271,"amplitude":0.002955,"askPrice":65.18,"askSize":100,"bidPrice":21.73,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":42.3399,"sharesOutstanding":650000,"nav":43.201,"aum":32400497.63,"dividendRate":0.003321,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.3608,"preClose":43.3608,"latestTime":"16:10 EDT","volume":6,"amount":260.1648,"timestamp":1787688604286,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.751318,"impliedVol":0.0938,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.751318,"shares":750000,"dividePrice":0.144,"high":43.4001,"amplitude":0.002955,"preClose":42.3399,"low":43.275,"week52Low":29.5,"pbRate":"--","week52High":43.4001,"institutionHeld":0,"latestPrice":43.3608,"committee":0.333333,"eps":0,"divideRate":0.003321,"volume":513,"delay":0,"ttmEps":0,"open":43.4001,"prevYearClose":36.3062,"prevWeekClose":43.11,"prevMonthClose":38.8312,"prevQuarterClose":39.9651,"fiveDayClose":40.9918,"twentyDayClose":39.1286,"sixtyDayClose":34.2035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140094349","title":"Metabolic disorder biotech Vogenx targets $75 million IPO at $11-$13 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1140094349","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140094349?lang=en_us&edition=fundamental","pubTime":"2026-07-30 16:23","pubTimestamp":1785399812,"startTime":"0","endTime":"0","summary":"Metabolic disorder-focused biotechnology company Vogenx (VOGX.US) announced the terms of its initial public offering on Wednesday. The company, which is currently advancing a Phase 2b clinical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","WDNA","HELX","IPOS","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655846515","title":"Natera CFO Michael Burkes Brophy Disposes of USD 1.29 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655846515","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655846515?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:35","pubTimestamp":1785375339,"startTime":"0","endTime":"0","summary":"Natera CFO Michael Burkes Brophy disposes of USD 1.29 million in common sharesNatera CFO Michael Burkes Brophy sold 5,064 common shares on July 27-29, 2026.Sales prices ranged from USD 249.38 to USD 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL5TDhd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera CFO Michael Burkes Brophy Disposes of USD 1.29 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","NTRA","LU2324357040.USD","LU2264538146.SGD","LU2065171402.SGD","LU0053671581.USD","GNOM","LU0963586101.USD","LU2065731478.USD","LU1064131342.USD","LU2065169927.USD","LU0106261612.USD","HELX","LU0012050646.USD","LU0345770308.USD","LU0345770993.USD","LU1988902786.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655810567","title":"Adaptive Biotechnologies Corp Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655810567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655810567?lang=en_us&edition=fundamental","pubTime":"2026-07-30 06:45","pubTimestamp":1785365155,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings SummaryAdaptive Biotechnologies CorpADPT.OQreported a quarterly adjusted loss of 10 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL8N43V3RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655819299","title":"Adaptive Biotechnologies Q2 Net Loss Widens to $39.9 Million; Revenue Rises 22% to $71.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655819299","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655819299?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:28","pubTimestamp":1785356890,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Q2 net loss widens to $39.9 million; revenue rises 22% to $71.6 millionAdaptive Biotechnologies posted Q2 revenue of USD 71.6 million, up 22% year over year, while net loss wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL9gSPcr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","ADPT","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","BCDF","SG9999014021.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4588","BK4121","IE00B64PRP62.GBP","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816007","title":"Adaptive Biotechnologies Shares Drop 6.9% in Extended Trading After Posting Quarterly Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816007?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:17","pubTimestamp":1785356275,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL6N43V1C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816518","title":"Guardant Health to Present at Canaccord Genuity Growth Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816518?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:09","pubTimestamp":1785355797,"startTime":"0","endTime":"0","summary":"Guardant Health to present at Canaccord Genuity growth conference fireside chatGuardant Health will join the Canaccord Genuity 46th Annual Growth Conference on Aug. 12, featuring a 3:00 p.m. ET firesi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL69rpsx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","HELX","BK4534","FFOX","LU1244550577.SGD","LU0314104364.USD","BK4581","LU2271345857.HKD","LU1791710400.SGD","LU0006306889.USD","LU0053666078.USD","LU1162221912.USD","LU1074936037.SGD","BK4588","LU1668664300.SGD","LU1720051017.SGD","PTH","LU1732800096.USD","LU0098860793.USD","IE00BZ1G4Q59.USD","GH","LFSC","KBWB","LU0795875169.SGD","LU1720051108.HKD","LU0109394709.USD","LU0225283273.USD","LU0320765646.SGD","LU1244550221.USD","LU2023251221.USD","GDOC","LU2264538146.SGD","BK4585","BK4551","LU2089283258.USD","LU2089284900.SGD","LU0889565916.HKD","GNOM","IAI","BK4516","LU0557290698.USD","LU0267386448.USD","LU1548497426.USD","EKG","GNMX","LU1989772840.SGD","LU0912757837.SGD","BK4504","LU0210528500.USD","LU0158827781.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816352","title":"Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816352","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816352?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:07","pubTimestamp":1785355637,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.14) by 78.57 percent. This is a 47.06 percent decrease over losses of $(0.17) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60779108/adaptive-biotechnologies-q2-eps-0-25-misses-0-14-estimate-sales-71-553m-beat-65-886m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867816","title":"Adaptive Biotechnologies Q2 EPS USD -0.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655867816?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:06","pubTimestamp":1785355564,"startTime":"0","endTime":"0","summary":"BRIEF-Adaptive Biotechnologies Q2 EPS USD -0.25Jul 29  - Adaptive Biotechnologies Q2 revenue USD 71.553 million vs. IBES estimate USD 65.9 million.Q2 operating expenses USD 87.323 millionQ2 net income USD -39.941 millionQ2 operating income USD -15.77 millionQ2 adjusted EBITDA USD -700 thousand","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nPLXRSZH5P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655845814","title":"Adaptive Biotechnologies Expects Fy2026 Mrd Revenue $268 Mln-$278 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2655845814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655845814?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:05","pubTimestamp":1785355506,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nPLXRSZH5P:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655025815","title":"Adaptive Biotechnologies Q2 Adjusted Ebitda USD -700 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2655025815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655025815?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:05","pubTimestamp":1785355506,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nPLXRSZH5P:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655815074","title":"Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655815074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655815074?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:05","pubTimestamp":1785355504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA2QBNQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655869897","title":"ABL Diagnostics Reports Share Block Sale by Main Shareholder and Reaffirms Market Visibility Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2655869897","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655869897?lang=en_us&edition=fundamental","pubTime":"2026-07-30 00:40","pubTimestamp":1785343248,"startTime":"0","endTime":"0","summary":"The latest update is out from ABL Diagnostics SA ( ($FR:ABLD) ). ABL Diagnostics SA, a publicly listed French molecular diagnostics specialist, dev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abl-diagnostics-reports-share-block-sale-by-main-shareholder-and-reaffirms-market-visibility-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abl-diagnostics-reports-share-block-sale-by-main-shareholder-and-reaffirms-market-visibility-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","HTEC","HELX","ABLD","DAPP","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036232","title":"Natera’s New ctDNA-Guided Immunotherapy Trial Could Redefine Cancer Treatment Cycles","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036232?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:33","pubTimestamp":1784910804,"startTime":"0","endTime":"0","summary":"Natera Inc. ($NTRA) announced an update on their ongoing clinical study. Natera, Inc. has launched a new trial titled “A Multicenter Randomized Ope...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nateras-new-ctdna-guided-immunotherapy-trial-could-redefine-cancer-treatment-cycles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nateras-new-ctdna-guided-immunotherapy-trial-could-redefine-cancer-treatment-cycles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","LU1064131342.USD","LU0106261612.USD","LU1988902786.USD","LU0345770993.USD","LU2065169927.USD","GNOM","LU0053671581.USD","LU2065731478.USD","LU0963586101.USD","LU2065170008.USD","LU0012050646.USD","LU2065171402.SGD","NTRA","LU2065171311.SGD","LU2264538146.SGD","LU2324357040.USD","LU0345770308.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774168","title":"Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774168","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774168?lang=en_us&edition=fundamental","pubTime":"2026-07-24 07:35","pubTimestamp":1784849727,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies CSO Harlan S. Robins reports disposal of common shares worth $10.77 millionAdaptive Biotechnologies Chief Scientific Officer Harlan S. Robins exercised options for 284,800 com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL5cmyfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653776725","title":"Krystal Biotech Updates Financial Calendar with Quarterly Results Release, Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2653776725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653776725?lang=en_us&edition=fundamental","pubTime":"2026-07-24 05:01","pubTimestamp":1784840492,"startTime":"0","endTime":"0","summary":"Krystal Biotech updates financial calendar with quarterly results release, conference callSecond-quarter 2026 financial results scheduled for release on Aug. 3, 2026, before the U.S. market open.Confe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL3BPkQn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","PSCH","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BCDF","HELX","SG9999014039.USD","SG9999014013.SGD","BK4588","KRYS","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653659747","title":"Natera (NTRA) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2653659747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653659747?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:38","pubTimestamp":1784806705,"startTime":"0","endTime":"0","summary":"BTIG analyst Mark Massaro maintained a Buy rating on Natera yesterday and set a price target of $290.00. The company’s shares closed yesterday at $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/natera-ntra-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/natera-ntra-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0963586101.USD","BK4139","LU0106261612.USD","LU0012050646.USD","LU0053671581.USD","LU0345770308.USD","LU2065171311.SGD","GNOM","LU1064131342.USD","LU2065171402.SGD","LU2324357040.USD","NTRA","LU1988902786.USD","LU2065731478.USD","LU0345770993.USD","LU2065169927.USD","HELX","LU2065170008.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653675057","title":"J.P. Morgan Remains a Buy on Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653675057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653675057?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:17","pubTimestamp":1784722675,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Casey Woodring from J.P. Morgan maintained a Buy rating on Natera, with a price target of $315.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-natera-ntra-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-natera-ntra-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KBWB","LU2089283258.USD","LU2133065610.SGD","LU0210528500.USD","BK4127","HELX","BK4585","LU2065171311.SGD","LU2357305700.SGD","NTRA","IAI","LU2347655156.SGD","LU1989772840.SGD","LU1162221912.USD","LU1791710582.SGD","LU1244550221.USD","LU1732800096.USD","LU0053666078.USD","LU0234570918.USD","BK4516","LU0098860793.USD","LU1720051017.SGD","LU0225283273.USD","LU1988902786.USD","LU2111349929.HKD","LU2065169927.USD","LU0795875086.SGD","LU1732799900.SGD","LU0106261612.USD","LU1791710400.SGD","LU0345770308.USD","LU2324357040.USD","LU1064131342.USD","LU1720051108.HKD","LU2271345857.HKD","LU0158827948.USD","LU2065731478.USD","LU1244550577.SGD","LU0106261372.USD","LU2028103732.USD","GNOM","LU0345770993.USD","LU0971096721.USD","BK4581","LU2065171402.SGD","LU0320765646.SGD","IE00BKVL7J92.USD","LU1244550494.USD","LU0006306889.USD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653597907","title":"Natera reports results from multicenter study in MCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2653597907","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653597907?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:10","pubTimestamp":1784715027,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma, or MCC, published in JAMA Dermat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-reports-results-from-multicenter-study-in-mcc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-reports-results-from-multicenter-study-in-mcc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345770308.USD","LU2065171402.SGD","LU2065731478.USD","LU0012050646.USD","LU0106261612.USD","LU0053671581.USD","LU1988902786.USD","LU2065171311.SGD","GNOM","LU1064131342.USD","NTRA","BK4139","LU2324357040.USD","LU2065170008.USD","LU2264538146.SGD","LU0345770993.USD","LU2065169927.USD","HELX","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653759335","title":"Natera Notifies Availability of Press Release on Signatera Merkel Cell Carcinoma Study in JAMA Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759335","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653759335?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:01","pubTimestamp":1784714469,"startTime":"0","endTime":"0","summary":"Natera notifies availability of press release on Signatera Merkel cell carcinoma study in JAMA DermatologyNatera released a press release on a JAMA Dermatology study comparing Signatera MRD with AMERK in Merkel cell carcinoma surveillance.Head-to-head analysis in 169 patients showed Signatera was a stronger recurrence predictor than AMERK .Signatera sensitivity was 90% versus 55% for AMERK, with earlier detection in dual-positive cases .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire  on July 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL7jNlGx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","NTRA","LU0012050646.USD","LU2065169927.USD","BK4139","LU2065170008.USD","LU0963586101.USD","LU0345770308.USD","LU0053671581.USD","LU2065731478.USD","LU0106261612.USD","LU2264538146.SGD","LU2065171311.SGD","LU2065171402.SGD","GNOM","LU0345770993.USD","LU1988902786.USD","LU2324357040.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653735352","title":"Is Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653735352","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653735352?lang=en_us&edition=fundamental","pubTime":"2026-07-22 11:30","pubTimestamp":1784691056,"startTime":"0","endTime":"0","summary":"Why KB801’s Patent Filing Matters For Krystal Biotech Stock\nKrystal Biotech (KRYS) recently filed a response with the U.S. Patent and Trademark Office for KB801, sharing previously undisclosed single patient data on corneal defect closure from a discontinued neurotrophic keratitis study.\nThe company stressed that this observation comes from one patient and is not a substitute for clinical trial results. However, the disclosure offers investors a clearer view of how KB801 is progressing toward...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/is-krystal-biotech-krys-overvalued-on-its-kb801-patent-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/is-krystal-biotech-krys-overvalued-on-its-kb801-patent-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","PSCH","BK4581","BK4139","BK4588","XBI","KRYS","BK4585","HELX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}